highgreennews

Amidst the COVID-19 pandemic, a new report expects Canada’s recreational marijuana industry to double revenues this year and grow more than 500% by 2025. This should be good news for cannabis ETFs, many of which are far off their highs.

In October 2018, Canada became the second country to make recreational cannabis legal nationwide. This sparked a huge rally in cannabis stocks, such as Canopy Growth (CGC) and Tilray (TLRY). It also sent ETFs focused on the cannabis industry surging. 

Very simply, marijuana legalization is not some wild experiment that has never been done before. And now, of course, we are beginning to see the same experience in some places in the United States.

In the midst of the pandemic, there is much uncertainty about almost everything, but one thing does seem certain: America is going to be much poorer. Or, to put in a global perspective, America and a few other countries will be much less rich and the rest of the world will be much, much poorer, and no wall or welfare program will protect us.

Bills focused on a state bank, delivery, and curbing the illicit market failed to make it through this legislative session.

While Californians voted to legalize cannabis four years ago, lawmakers continue to debate and tweak regulations for the world’s largest legal cannabis market. 

This year, COVID-19 caused legislative delays from coast to coast. Some states’ legislative sessions ended early, while lawmakers in other states were forced to shift focus to discussions about coronavirus-related bills. 

A degree “definitely gives you more credibility and shows that you have a baseline of cannabis knowledge,” according to a long-time cannabis industry educator and advocate.

Aside from marijuana-specific institutions like Oaksterdam University, there weren’t many cannabis classes being offered in America’s college classrooms.

The tide is beginning to turn as a range of institutions are now embracing marijuana and its career prospects.

Although research in the U.S. has been limited for decades, researchers around the globe are leading the charge.

While standards are a necessary part of every industry, the pharmacological space is not free from corruption. Additional research is always a boon for understanding, but the demands put on cannabis by the United States Federal Government are uniquely restrictive.

A pair of in-house lawyers with high hopes for legal cannabis products are moving up in the C-suite, while a longtime health and fitness industry legal chief has found a home in the legal weed space.

The California Department of Tax and Fee Administration reported today that cannabis legalization and taxation in the state came in the nick of time. Just when the state is under extreme fiscal pressure, cannabis is pulling through: Cannabis tax revenues in the second quarter soared 32.6% from a year ago, to another record of $208.4 million (not including revenues collected by cities and counties). And this during the Pandemic!

The FDA announced it is hiring a third-party contractor to test CBD “and related cannabinoids” for the agency.

The Food and Drug Administration has posted notice for a contractor to test CBD “and related cannabinoids.” The announcement comes less than a month after the agency called for public comments on its guidance for cannabis-derived pharmaceutical research.

The state of New York will not submit a state hemp plan to the U.S. Department of Agriculture (USDA), saying the federal program‘s requirements are too strict on growers. The announcement effectively puts on hold the New York State Department of Agriculture and Markets’ hemp program.

One of the biggest threats facing CBD companies? Survival. CBD is already projected to hit over $16 billion in sales by 2024, so it's not surprising that there are over 3,000 brands in the market, hoping to ride the wave of success and reap the rewards.